Hubungan Jenis dan Siklus Kemoterapi dengan Derajat Neuropati pada Pasien Keganasan
DOI:
https://doi.org/10.35790/msj.v6i2.53140Abstract
Abstract: Antineoplastic chemotherapy agents in cancer treatment can cause peripheral neuropathy. Antineoplastic agents associated with chemotherapy-induced peripheral neuropathy include platinum-based drugs (carboplatin, cisplatin and oxaliplatin) and taxane (paclitaxel and docetaxel). This study aimed to evaluate the relationship between the type and cycle of chemotherapy with the level of neuropathy in malignant patients at Prof. Dr. R. D. Kandou Hospital, Manado, in 2022. The results obtained 43 cancer patients aged 18-65 who underwent chemotherapy, especially drugs from the platinum group (81.4%) such as oxaliplatin (62.8%). The majority of cases were colorectal adenocarcinoma (63%). Using the Toronto Score, the majority of subjects experienced mild neuropathy (55.8%), followed by without neuropathy (32.5%) and moderate neuropathy (11.6%). Although there was an indication of a relationship between the type of chemotherapy and the severity of neuropathy, the results were not statistically significant (p=0.069). In conclusion, there is no relationship between the type and cycle of chemotherapy with the level of neuropathy in cancer patients.
Keywords: neuropathy; chemotherapy cycles; types of chemotherapy
Abstrak: Agen kemoterapi antineoplastik dalam pengobatan kanker dapat menyebabkan neuropati perifer. Agen antineoplastik terkait neuropati perifer yang diinduksi kemoterapi termasuk obat berbasis platinum (carboplatin, cisplatin dan oxaliplatin) dan taxane (paclitaxel dan docetaxel). Penelitian ini bertujuan untuk mengetahui hubungan jenis dan siklus kemoterapi dengan keparahan neuropati pada pasien keganasan di RSUP Prof. Dr. R. D. Kandou Manado pada tahun 2022. Hasil penelitian mendapatkan 43 pasien kanker berusia 18-65 tahun yang telah menjalani kemoterapi, khususnya obat berbasis platinum (81,4%) seperti oxaliplatin (62,8%). Jenis keganasan yang terbanyak ialah adenokarsinoma kolorektal (63%). Dengan menggunakan Skor Toronto, didapatkan mayoritas subjek mengalami neuropati ringan (55,9%) diikuti tanpa neuropati (32,5%) dan neuropati sedang (11,6%). Meski ada indikasi hubungan antara jenis kemoterapi dengan tingkat neuropati, hasilnya tidak bermakna secara statistik (p=0,069). Simpulan penelitian ini ialah tidak terdapat hubungan antara jenis dan siklus kemoterapi dengan tingkat neuropati pada pasien keganasan.
Kata kunci: neuropati; siklus kemoterapi; jenis kemoterapi
References
Cioroiu C, Weimer LH. Update on chemotherapy-induced peripheral neuropathy. Curr Neurol Neurosci Rep. 2017;17(6):47. Doi:10.1007/s11910-017-0757-7
Hu LY, Mi WL, Wu GC, Wang YQ, Mao-Ying QL. Prevention and treatment for chemotherapy-induced peripheral neuropathy: therapies based on CIPN mechanisms. Curr Neuropharmacol. 2019;17(2):184-96. Doi:10.2174/1570159X15666170915143217
Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451. Doi:10.3390/ ijms20061451
Banach M, Juranek JK, Zygulska AL. Chemotherapy-induced neuropathies-a growing problem for patients and health care providers. Brain Behav. 2017;7(1):e00558. Doi:10.1002/brb3.558
Makker PGS, Duffy SS, Lees JG, Perera CJ, Tonkin RS, Butovsky O, et al. Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PLoS One. 2017;12(1):e0170814. Doi:10.1371/journal.pone.0170814
Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772-81. Doi:10.1002/ana.24951
Hertz DL, Childs DS, Park SB, Faithfull S, Ke Y, Ali NT, et al. Patient-centric decision framework for treatment alterations in patients with chemotherapy-induced peripheral neuropathy (CIPN). Cancer Treat Rev. 2021;99:102241. Doi:10.1016/j.ctrv.2021.102241
Shah A, Hoffman EM, Mauermann ML, Loprinzi CL, Windebank AJ, Klein CJ, et al. Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. J Neurol Neurosurg Psychiatry. 2018;89(6): 636-41. Doi:10.1136/jnnp-2017-317215
Kleckner IR, Kamen C, Gewandter JS, Mohile NA, Heckler CE, Culakova C, et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer. 2018;26(4):1019-28. Doi:10.1007/s00520-017-4013-0
Hung HW, Liu CY, Chen HF, Chang CC, Chen SC. Impact of chemotherapy-induced peripheral neuropathy on quality of life in patients with advanced lung cancer receiving platinum-based chemotherapy. Int J Environ Res Public Health. 2021;18(11):5677. Doi:10.3390/ijerph18115677
Calls A, Torres-Espin A, Navarro X, Yuste VJ, Udina E, Bruna J. Cisplatin-induced peripheral neuropathy is associated with neuronal senescence-like response. Neuro Oncol. 2021;23(1):p88-99. Doi:10.1093/neuonc/noaa151
Le-Rademacher J, Kanwar R, Seisler D, Pachman DR, Qin R, Abyzov A, et al. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/ carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials. Support Care Cancer. 2017;25(11): 3537-44. Doi:10.1007/s00520-017-3780-y
Kang L, Tian Y, Xu S, Chen H. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment. J Neurol. 2021;268(9):p3269-82. Doi:10.1007/s00415-020-09942-w
Kim SH, Kim W, Kim JH, Woo MK, Baek JY, Kim SY, et al. A prospective study of chronic oxaliplatin-induced neuropathy in patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy. J Clin Neurol. 2018;14(1):p81-9. Doi:10.3988/jcn.2018.14.1.81
Briani C, Argyriou AA, Izquierdo C, Velasco R, Campagnolo M, Alberti P, et al. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. J Peripher Nerv System. 2014;19(4):299-306. Doi:10.1111/jns.12097
Yoshino T, Kotaka M, Shinozaki K, Touyama T, Manaka D, Matsui T, et al. JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer. Cancer Chemother Pharmacol. 2019;84(6):1269-77. Doi:10.1007/s00280-019-03957-5
Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK, et al. Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy. Brain Behav. 2019;9(6):e01312. Doi:10.1002/brb3.1312
Eckhoff L, Knoop AS, Jensen MB, Ewertz M. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer. 2015;51(3):292-300. Doi:10.1016/j.ejca.2014.11.024
Pabst L, Velten M, Fischbach C, Kalish M, Pflumio C, Pivot X, et al. Persistent taxane induced neuropathy in elderly patients treated for localized breast cancer. Breast J. 2020;26(12):2376-82. Doi:10.1111/tbj.14123
Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M, et al. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol. 2013;18(1):132-8. Doi:10.1007/s10147-011-0352-x
Hou S, Huh B, Kim HK, Kim KH, Abdi S. Treatment of chemotherapy-induced peripheral neuropathy: systematic review and recommendations. Pain Physician. 2018;21(6):571-92. Available from: https://pubmed.ncbi.nlm.nih.gov/30508986/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Harlinda Haroen, Indriaty Gimon
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
COPYRIGHT
Authors who publish with this journal agree to the following terms:
Authors hold their copyright and grant this journal the privilege of first publication, with the work simultaneously licensed under a Creative Commons Attribution License that permits others to impart the work with an acknowledgment of the work's origin and initial publication by this journal.
Authors can enter into separate or additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (for example, post it to an institutional repository or publish it in a book), with an acknowledgment of its underlying publication in this journal.
Authors are permitted and encouraged to post their work online (for example, in institutional repositories or on their website) as it can lead to productive exchanges, as well as earlier and greater citation of the published work (See The Effect of Open Access).
